UK NICE Changes Mind On Ocrevus After Roche Drops Price

 
• By Neena Brizmohun

Health technology assessment body NICE has changed its mind about the use of Ocrevus for treating primary progressive multiple sclerosis after Roche offered a lower price for the drug.

healthcare-costs
NICE says Ocrevus is now a cost-effective use of NHS resources for PPMS • Source: Shutterstock

More from Health Technology Assessment

More from Market Access